Loading people...
Klaus Veitinger is a Venture Partner at OrbiMed, focusing on venture investments within the therapeutic space. Prior to joining the investment firm, he spent 16 years in the pharmaceutical industry, culminating as Chief Executive Officer of Schwarz Pharma Inc. In this capacity, he oversaw the company's United States and Asian operations until the sale of the broader Schwarz Group. During his corporate career, he also served a seven-year tenure as a Director of PhRMA. As an investor, Veitinger has spent over 15 years supporting venture-backed life sciences companies, holding board positions at numerous portfolio entities including Neurogastrx, where he serves as Chairman, and Sparrow Pharmaceuticals. He holds an MD and PhD from the University of Heidelberg and an MBA from INSEAD, underpinning his current focus on advancing clinical-stage drug development, licensing, and global commercial operations.
Klaus Veitinger, MD, PhD, serves as a highly respected Venture Partner at OrbiMed, one of the world's largest and most active healthcare-dedicated investment firms. In this pivotal role, Klaus Veitinger is instrumental in shaping the future of healthcare by identifying and investing in groundbreaking companies that promise to deliver significant advancements in patient care and medical science. His work at OrbiMed encompasses a broad spectrum of investment activities, from early-stage venture capital to growth equity, focusing on companies developing novel therapeutics, diagnostics, medical devices, and digital health solutions.
Klaus Veitinger's investment focus areas are deeply rooted in his profound understanding of the life sciences industry. He targets opportunities within biotechnology and pharmaceuticals, particularly those addressing unmet medical needs in areas such as oncology, rare diseases, immunology, and central nervous system disorders. His strategic insights are invaluable in evaluating the scientific merit, clinical potential, and market viability of prospective investments, ensuring that OrbiMed's capital is deployed to foster genuine innovation.
Prior to joining OrbiMed in 2010, Klaus Veitinger built an impressive career marked by significant leadership positions within the global pharmaceutical industry. He notably served as President of Pharmaceuticals at Bayer Healthcare, where he oversaw substantial growth and strategic initiatives. Before his tenure at Bayer, he held the position of CEO of Schering Berlin Inc., contributing to the company's success and market presence. His extensive operational experience at major pharmaceutical corporations provides him with a unique perspective on drug development, commercialization, and regulatory landscapes, which he now applies to guide OrbiMed's portfolio companies.
Klaus Veitinger's career background also includes a strong foundation in medicine and research, holding both an MD and a PhD. This dual expertise allows him to critically assess scientific data and clinical trial designs, making him a highly effective partner for entrepreneurial teams in the healthcare sector. His leadership extends to serving on the boards of numerous public and private biotechnology companies, where he provides strategic guidance and governance. Through his work at OrbiMed, Klaus Veitinger continues to be a driving force in advancing healthcare innovation, supporting companies that are poised to make a lasting impact on global health.
Klaus Veitinger, MD, PhD, is a distinguished Venture Partner at OrbiMed, a leading global healthcare-focused investment firm. He is known for his extensive experience in the pharmaceutical industry and his strategic investments in innovative healthcare companies.
Klaus Veitinger primarily invests in companies within the healthcare sector, focusing on biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. He targets innovative companies developing novel therapeutics and technologies that address significant medical needs.
Klaus Veitinger works as a Venture Partner at OrbiMed, a premier global healthcare-dedicated investment firm. OrbiMed invests across the full spectrum of healthcare companies, from early-stage private firms to large multinational corporations.
